טיפול משולב לסרטן ריאות של תאים לא קטנים החיובי למוטציה ב- egfr
- 专利权人:
- MEDIMMUNE LIMITED
- 发明人:
- 申请号：
- IL25505817
- 公开号：
- IL255058D0
- 申请日:
- 2017.10.16
- 申请国别(地区):
- IL
- 年份:
- 2017
- 代理人:
- 摘要：
- The present invention features methods of treating lung cancer (e.g., NSCLC) with an anti-PD-L1 antibody and a tyrosine kinase inhibitor in a subject identified as having an EGFR mutation-positive tumor.
- 来源网站：
- 中国工程科技知识中心
相关发明人
相关专利
- Combination therapy of non-small cell lung cancer positive for EGFR mutation
- COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION
- Combination therapy for non-small cell lung cancer positive for EGFR mutation
- COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION
- COMBINATION THERAPY FOR NON-SMALL CELL LUNG CANCER POSITIVE FOR EGFR MUTATION
